Table 4. Telomere length and telomerase activity as predictors of the primary composite outcome.
| Hazard ratio | 95% confidence interval | p-value | |
|---|---|---|---|
| Model 1 | |||
| TL* | |||
| MTL | 1.28 | 0.56–2.91 | 0.56 |
| STL | 1.50 | 0.68–3.34 | 0.32 |
| TA† | |||
| Mid | 0.90 | 0.94–2.60 | 0.89 |
| Low | 1.33 | 0.52–3.36 | 0.51 |
| Model 2 | |||
| TL* | |||
| MTL | 1.49 | 0.64–3.45 | 0.35 |
| STL | 1.58 | 0.71–3.55 | 0.26 |
| TA† | |||
| Mid | 1.04 | 0.37–2.92 | 0.94 |
| Low | 1.18 | 0.46–3.06 | 0.73 |
Univariate (model 1) and multivariate (model 2; adjusted for age, gender and frailty) Cox regression analysis preformed for combined and primary outcomes alone using telomere length and telomerase activity as predictors. Both predictors were divided into tertiles for analysis.
* LTL used as reference.
† High used as reference. MTL- medium telomere length, STL-short telomere length and TA-telomerase activity.